ArticleThe American journal of gastroenterology2015
SOX2 as a novel marker to predict neoplastic progression in Barrett's esophagus.
Article in The American journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Pooled it
- Transcriptomic comparative study between canalicular adenoma and HMGA2::WIF1 canalicular-like pleomorphic adenoma.The Journal of pathology · 2026Article
- Spatial SRY-Box Transcription Factor 2 Expression and Stemness-Associated Markers Refine Risk Stratification in Barrett's Esophagus: A Digital Pathology Study of 217 Patients.Journal of clinical medicine research · 2026Article
- Molecular biomarkers of progression from Barrett's esophagus to esophageal adenocarcinoma.Frontiers in gastroenterology (Lausanne, Switzerland) · 2023Article
- Evolutionary dynamics in Barrett oesophagus: implications for surveillance, risk stratification and therapy.Nature reviews. Gastroenterology & hepatology · 2022Review
- A personalized and dynamic risk estimation model: The new paradigm in Barrett's esophagus surveillance.PloS one · 2022Article
- Identification of key genes associated with esophageal adenocarcinoma based on bioinformatics analysis.Annals of translational medicine · 2021Article
- Immune microenvironment in Barrett's esophagus adjacent to esophageal adenocarcinoma: possible influence of adjacent mucosa on cancer development and progression.Virchows Archiv : an international journal of pathology · 2020Article
- The cyclical hit model: how paligenosis might establish the mutational landscape in Barrett's esophagus and esophageal adenocarcinoma.Current opinion in gastroenterology · 2019Review
- Are Gastric and Esophageal Metaplasia Relatives? The Case for Barrett's Stemming from SPEM.Digestive diseases and sciences · 2018Review
- Increased SOX2 expression in salivary gland carcinoma ex pleomorphic adenoma progression: an association with adverse outcome.Virchows Archiv : an international journal of pathology · 2017Article
- Loss of SRY-box2 (SOX2) expression and its impact on survival of patients with oesophageal adenocarcinoma.The British journal of surgery · 2017Article
- Increased NG2 and SOX2 expression is associated with high-grade choroid plexus tumors.Oncology letters · 2017Article
- Article
- Monitoring the premalignant potential of Barrett's oesophagus'.Frontline gastroenterology · 2016Review
- Stomach Organ and Cell Lineage Differentiation: from Embryogenesis to Adult Homeostasis.Cellular and molecular gastroenterology and hepatology · 2016Article
- Dynamics of SOX2 and CDX2 Expression in Barrett's Mucosa.Disease markers · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe value of Barrett's esophagus (BE) surveillance based on the histological diagnosis of low-grade dysplasia (LGD) remains debated given the lack of adequate risk stratification. The aim of this study was to evaluate the predictive value (PV) of SOX2 expression for neoplastic progression in BE patients.
methodsWe conducted a case-control study within a prospective cohort of 720 BE patients. Patients with neoplastic progression, defined as the development of high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC), were classified as cases and patients without neoplastic progression were classified as controls. SOX2 expression was determined by immunohistochemistry in more than 12,000 biopsies from 635 patients; these results were combined with our previous p53 immunohistochemical data.
resultsNondysplastic BE showed homogeneous nuclear staining for SOX2, whereas SOX2 was progressively lost in dysplastic BE. Loss of SOX2 was seen in only 2% of biopsy series without dysplasia, in contrast to 28% in LGD and 67% in HGD/EAC. Loss of SOX2 expression was associated with an increased risk of neoplastic progression in BE patients after adjusting for gender, age, BE length, and esophagitis (adjusted relative risk 4.8; 95% CI 3.2-7.0). The positive PV for neoplastic progression increased from 16% with LGD alone to 56% with concurrent loss of SOX2 and aberrant p53 expression.
conclusionsSOX2 expression is lost during transition from nondysplastic BE to HGD/EAC, and it is associated with an increased risk of neoplastic progression. The highest PV is achieved by concurrent loss of SOX2 and aberrant p53 expression in BE patients with LGD. The use of these markers has the potential to significantly improve risk stratification of Barrett surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.